Literature DB >> 11086050

The TNF receptor family member CD30 is not essential for negative selection.

A L DeYoung1, O Duramad, A Winoto.   

Abstract

CD30 is a member of the TNF receptor superfamily that has been implicated in negative selection and some forms of peripheral tolerance. A previous study of CD30(-/-) mice in a class I-restricted H-Y TCR-transgenic mouse model showed that CD30 is essential for removal of autoreactive thymocytes. During the course of the studies of CD30 in the class II-restricted TCR-transgenic mice, we found that the absence of CD30 has no effect on negative selection. Surprisingly, we also found that the CD30 mutation does not perturb apoptosis of the autoreactive thymocytes in the class I-restricted H-Y TCR-transgenic model. The minimal role of CD30 in negative selection and other recent data are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086050     DOI: 10.4049/jimmunol.165.11.6170

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Are we really on the right TRAIL?

Authors:  Erika Cretney; Adam P Uldrich; Stuart P Berzins; Andreas Strasser; Dale I Godfrey; Mark J Smyth
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Authors:  Robert Zeiser; Vu H Nguyen; Jing-Zhou Hou; Andreas Beilhack; Elizabeth Zambricki; Martin Buess; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 4.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

5.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.

Authors:  Joanne Fanelli Panus; Craig A Smith; Caroline A Ray; Terri Davis Smith; Dhavalkumar D Patel; David J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 6.  Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

Review 7.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 8.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors:  Geetika Bhatt; Kami Maddocks; Beth Christian
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

10.  Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.